摘要
目的:研究分子标记物表皮生长因子受体(EGFR)、人表皮生长因子受体-2(HER2)预测食管鳞状细胞癌同步放化疗敏感性的价值。方法:回顾分析59例T3-4,N和M分期不限的食管鳞状细胞癌患者同步放化疗效果,免疫组织化学方法检测EGFR,HER2,血管内皮生长因子(VEGF)、增殖细胞核抗原(PCNA),p53和K i-67在肿瘤组织中的表达,内镜复查评估疗效。结果:EGFR与HER2阳性组完全缓解率分别为63.6%(14/22),65.0%(13/20),阴性组完全缓解率分别为32.4%(12/37),33.3%(13/39),两组差异有统计学意义(P=0.030,P=0.028)。其他分子标记与食管鳞状细胞癌同步放化疗完全缓解率无明显关系。Logistic多因素回归分析显示EGFR及HER2阳性与同步放化疗完全缓解率有显著性关系。结论:EGFR,HER2可能有助于预测食管鳞状细胞癌同步放化疗敏感性。
Objective： To identify molecular markers epithelial growth factor receptor（EGFR） and human epithelial growth factor receptor-2（HER2） to predict the sensitivity of chemoradiotherapy（CRT）in the esophageal squamous cell carcinoma（ESCC）.Methods： Viewed 59 patients with T3-4,N-any,and M-any ESCC treated with CRT.The expressions of EGFR,HER2,vascular endothelial growth factor（VEGF）,and proliferating cell nuclear antigen（PCNA）,p53,Ki-67 were investigated immunohistochemically in biopsy specimens obtained before treatment from all 59 patients.The immunoreactivities were compared with responsiveness to CRT,as evaluated by endoscopy. Results： The complete response rate（CR） of the tumor estimated by endoscopy was 63.6%（14/22）in patients in the EGFR positive group and 65.0%（13/20）in patients in the HER2 positive group,while the CR was 32.4%（12/37） in patients in the EGFR negative group and 33.3%（13/39）in patients in the HER2 negative group.The difference of CR between EGFR,HER2 positive and negative groups was significant（P=0.030,P=0.028）.The immunoreactivities of the other molecular markers did not show a significant correlation with the responsiveness to CRT.Multiple logistic regression analysis revealed that positive immunostaining for EGFR and HER2 was significantly correlated with CR for CRT in esophageal squamous cell carcinoma. Conclusion： These results suggest that EGFR and HER2 may help to predict the response of tumor to CRT in esophageal squamous cell carcinoma.
出处
《江苏大学学报（医学版）》
CAS
2009年第6期519-522,共4页
Journal of Jiangsu University：Medicine Edition
关键词
食管鳞状细胞癌
同步放化疗
表皮生长因子受体
人表皮生长因子受体-2
esophageal squamous cell carcinoma
chemoradiotherapy
epithelial growth factor receptor
human epithelial growth factor receptor-2
